Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[F-Tosca]

Her er posteren fra ASH 2019
https://www.nordicnanovector.com/sites/default/files/Poster%20ASH%202019%20-%![bilde|690x356

Takk til @Timm som postet linken først på småpraten.

[F-Tosca]

Skjermdump av konklusjonen

[ListeBot]

En fersk aksjonærliste for NANO er tilgjengelig. Trykk her for å se den. Krever Insider-medlemskap)

[Savepig]

Nordic Nanovector sin R&D avdeling sammen med Oslo Universitetssykehus presenterer poster på ASH:

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

Sebastian Patzke (Seb_Patzke)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to...

Her er posteren fra ASH 2019
https://www.nordicnanovector.com/sites/default/files/Poster%20ASH%202019%20-%![bilde|690x356

Takk til @Timm som postet linken først på småpraten.

[Savepig]

Graham Collins (graham74GC)

[TekBot]

Nordic Nanovector ASA: Allocation of PSUs

Oslo, Norway, 11 December 2019

The Board of Directors of Nordic Nanovector ASA (“Nordic Nanovector” or the
…

Vis børsmeldingen

“Company”) has on 10th December 2019 resolved to grant Dr Lars Nieba, Chief
Technology Officer, 50,000 Performance Share Units (“PSUs”) in connection with
his appointment and under the Company’s equity incentive plan that was approved
at the Company’s annual general meeting held on 25 April 2019 (the “AGM”). For
further information about Dr Lars Nieba see the Company’s stock exchange
announcement on 20 August 2019. Following the allocation, Dr Nieba holds 50,000
PSUs, 0 options and 0 shares in Nordic Nanovector.

In accordance with the resolution at the AGM the PSUs are secured by a
corresponding number of free-standing warrants. The sole purpose of the free
-standing warrants is to ensure delivery of shares in the Company upon exercise
of the PSUs. The free-standing warrants do not give the PSU-holder a right to
subscribe for any additional shares in the Company.

The terms and conditions of the PSUs, which are part of the Company’s long-term
incentive plan for employees, are described on pages 24-25 in the Company’s
annual report for 2018.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin[®], a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin[®] in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Securities
Trading Act, Sections 4-2 and 5-12 / Oslo Stock Exchange’s Continuing
Obligations, Section 3.2.

Kilde

[Savepig]

Lite innsidekjøp fra Lars og så blir det bra

[vegar_beider]

Ikke bra kortsiktig for de som venter på kursdrivende nyheter.
Bra for de som er loooong

[TekBot]

Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial

Oslo, Norway, 12 December 2019

Nordic Nanovector ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1
…

Vis børsmeldingen

trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell
lymphoma (R/R DLBCL) who are not eligible for autologous stem cell
transplantation (SCT). DLBCL is an aggressive form of non-Hodgkin’s lymphoma
(NHL) and accounts for up to 43% of all cases, making it the most common type of
NHL.

This open-label, dose-escalation safety trial is designed to assess the safety,
tolerability, pharmacokinetic profile and preliminary anti-tumour activity of
Betalutin® in up to 24 patients. The primary goal of the trial is to identify
the maximally tolerated dose of Betalutin® which will then be further evaluated
for safety and anti-tumour activity in an expansion cohort in order to select
the recommended dose for phase 2. Three additional patients are currently being
enrolled for further evaluation of the final dose cohort as one patient has
experienced a reversible DLT (dose limiting toxicity).

On the three completed cohorts, no safety issues were identified. Evidence of
disease control has been noted in some of the enrolled patients. We expect to
complete the data read-out for the dose-escalation phase and submit the data to
an international congress in 1H 2020.

Eduardo Bravo, Nordic Nanovector’s Chief Executive Officer, commented: “Patients
with relapsed/refractory DLBCL who are not eligible for stem cell
transplantation have very limited treatment options and a poor prognosis. As the
safety profile of Betalutin® will guide its potential for combination regimens
as well as single agent consolidation therapy, we look forward to completing
this part of the trial and proceeding with the expansion cohort.”

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Kilde

[amagad]

Ikke sikkert det er så galt

Evidence of
disease control has been noted in some of the enrolled patients.

Edit: Er vel bare 9 pas de har data på og some betyr jo mer enn 1 mine øyne
Edit2: …og er vel bare en fordel at de mener det er såpass at det bør på en kongress.

[hybrid]

La merke til den jeg også.

[Zuba]

Men hvorfor så begrensa info?

[FakeNews]

Dette er jo kjempe gode nyheter…

Betyr at Nano og J Dahle er på sporet av noe som er vert å undersøke?

Slik jeg tolker børs meldingen.

[TyrionIV]

Nja minst 3 stk med stable disease… ingen orr…? Avhengig av en kombi ihvertfall…

[anon21766851]

Huff. Disease controll tyder vel igrunn på ingen respons overhodet, i klinisk forstand.

[TyrionIV]

Omtrent ßom forventet

[Nocturne]

Hvorfor er read-out nå H1 2020?

Ingen data i år?

[hybrid]

SD i mono, jaja, ikke verst tenker jeg da. Bravo har jo sagt at de IKKE kommer til å kjøre betalutin som monobehandling i DLBCL.

Får nok en forklaring på det idag.

[vegar_beider]

Denne meldingen tror jeg ikke de hadde kommet med hadde det ikke vært for at de har lovet noe.
De er ikke ferdig med siste cohort så det er heller ikke en melding om ferdig innrullering.

Den er i beste fall svært vag.

Eneste konkrete her er at det ikke er noe safety issues i de 3 første cohortene- så langt, men det er vel ikke uventet.

[HBS]

Er dette her forklaringen på at det ved denne cohort står n=3+3 i beskrivelsen av studiet i blant annet Company presentation?

Da burde vi ha skjønt dette på forhånd…